

Title (en)
DIBENZOCYCLOHEPTANE COMPOUNDS AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS

Title (de)
DIBENZOCYCLOHEPTANVERBINDUNGEN UND PHARMAZEUTISCHE MITTEL, WELCHE DIESE VERBINDUNGEN ENTHALTEN

Title (fr)
DIBENZOCYCLOHEPTANES ET AGENTS PHARMACEUTIQUES CONTENANT CES COMPOSES

Publication
EP 1881968 A2 20080130 (DE)

Application
EP 06742900 A 20060512

Priority
• EP 2006004488 W 20060512
• DE 102005022020 A 20050512
• US 67996705 P 20050512

Abstract (en)
[origin: DE102005022020A1] Dibenzocycloheptane compounds (I) and their salt and solvate and its salts, are new. Dibenzocycloheptane compounds of formula (I) and their salt and solvate and its salts, are new. Either X, Y1 : CH 2, O, S, SO, SO 2or NR5; or X-Y1- : -(CH 2) 2- or -CH=CH-; R1 : H or 1-6C alkyl; R2 : H, halo or 1-4C alkyl-C?=C- (optionally substituted with amino group); R3 : -NH 2, phenyl compound of formula (a) or (b), cyclohexane compound of formula (c), -NH-1-6C alkylene-NH 2or halo; either R4 : H, halo or 1-6C alkyl; or CR3R4 : phenyl ring, 5-6 membered aromatic or non-aromatic heterocyclic ring with heteroatom such as N (where the heterocyclic ring is substituted with one or two 1-6C alkyl group or is condensed with a cyclohexyl group); R5, R6 : H or 1-6C alkyl; R7 : H, NH 2, mono-1-6C alkyl amino, di-1-6C alkylamino, 1-6C alkyl-CONH-, 1-6C alkyl-NHCONH-, 1-6C alkyl-O-CO-NH-, 1-6C alkyl, 1-6C alkoxy, NO 2or halo; R8 : H, NH 2, mono-1-6C alkylamino, di-1-6C alkylamino, 1-6C alkoxy or halo; and R9 : H or NH 2. [Image] [Image] ACTIVITY : Immunosuppressive; Cytostatic; Antiarthritic; Antirheumatic; Litholytic; Antibacterial; Osteopathic; Neuroprotective; Anti-HIV; Virucide; Antidiabetic; Antiinflammatory; Vasotropic; Endocrine-Gen.; Antipsoriatic; Antiarteriosclerotic; Immunomodulator; Nootropic; Cerebroprotective; Antiulcer; Gastrointestinal-Gen.; Cardiovascular-Gen.; Cardiant; Respiratory-Gen.; Hepatotropic; CNS-Gen.; Dermatological. MECHANISM OF ACTION : Interleukin-1beta inhibitor; Tumor necrosis factor-alpha inhibitor; Interleukin-1beta regulator; Tumor necrosis factor-alpha regulator. The ability of (I) to inhibit interleukin-1beta was tested using biological assays. The results showed that (I) exhibited an IC 50value of 1.8 mu M.

IPC 8 full level
C07D 313/12 (2006.01); **A61K 31/335** (2006.01); **A61P 29/00** (2006.01)

CPC (source: EP US)
A61P 1/02 (2018.01 - EP); **A61P 1/04** (2018.01 - EP); **A61P 1/16** (2018.01 - EP); **A61P 1/18** (2018.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 7/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 17/02** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 17/14** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 19/04** (2018.01 - EP); **A61P 19/06** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 21/00** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/04** (2018.01 - EP); **A61P 25/08** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 31/18** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 37/08** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07C 225/22** (2013.01 - EP US); **C07D 313/12** (2013.01 - EP US); **C07D 337/12** (2013.01 - EP US); **C07D 491/044** (2013.01 - EP US)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
DE 102005022020 A1 20061123; CA 2608889 A1 20061116; CN 101223153 A 20080716; EP 1881968 A2 20080130; JP 2008544952 A 20081211; US 2009105327 A1 20090423; WO 2006120010 A2 20061116; WO 2006120010 A3 20070118

DOCDB simple family (application)
DE 102005022020 A 20050512; CA 2608889 A 20060512; CN 200680022970 A 20060512; EP 06742900 A 20060512; EP 2006004488 W 20060512; JP 2008510505 A 20060512; US 91407806 A 20060512